Concepedia

Author

Colin Miles

Eli Lilly (United States)

Also Known As

C Miles, Colin Miles, Colin P Miles, Colin P. Miles

11

Publications

437

Citations

6

H-Index

0

Concepts

All Affiliations

Eli Lilly (United States)Heidelberg UniversityGoethe University FrankfurtEli Lilly (United Kingdom)Vall d'Hebron Hospital Universitari
CM

About

Colin Miles is an author at Eli Lilly (United States).

Colin Miles

×

5

Publications

408

Citations

5

H-Index

YearCitations

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Alba A. Brandes, Santosh Kesari, Juan Manuel Sepúlveda-Sánchez,

Neuro-Oncology

2016

264

Defining a therapeutic window for the novel <scp>TGF</scp>‐β inhibitor <scp>LY</scp>2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

Ivelina Gueorguieva, Ann Cleverly, Anja J. Stauber,

British Journal of Clinical Pharmacology

2013

79

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

David Capper, Andreas von Deimling, Alba A. Brandes,

International Journal of Molecular Sciences

2017

31

TC‐2559 excites dopaminergic neurones in the ventral tegmental area by stimulating<i>α</i>4<i>β</i>2‐like nicotinic acetylcholine receptors in anaesthetised rats

Yun Wang, J. L. Sherwood, Colin Miles,

British Journal of Pharmacology

2006

23

Disposition and metabolism of [<sup>14</sup>C]-galunisertib, a TGF-<b>β</b>RI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics

Kenneth C. Cassidy, Ivelina Gueorguieva, Colin Miles,

Xenobiotica

2017

11

Page 1